~~<i id='EC9FC14836'><strike id='EC9FC14836'><tt id='EC9FC14836'><pre id='EC9FC14836'></pre></tt></strike></i>~~

Home» knowledge» hotspot

hotspot

author：comprehensive 2025-10-06 09:12:55 Page View：12

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Obesity experts on risks of Wegovy, Ozempic weight loss drugs
Next article： How to save PrEP access — and even expand it

explore

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

1:04AframefromvideoreleasedbytheU.S.thatofficialssaidshowsdronesinSyriabeingharassedbyRussianjetsonW

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

New guidelines on severe brain injury complicate already difficult decisions

AdobeWhensomeonesustainsaseriousbraininjuryandisunresponsive,howsooncandoctorssaywhetherheorshehasac